Weight loss drug Contrave rejected, FDA says more tests needed
5 February, 2011
Weight Loss Drug Contrave rejected, FDA says more tests needed to figure out as to how much harmful is the drug for the users
The US Food and Drug Administration(FDA)’s refusal to approve a weight loss drug Contrave, citing heart risk has surprised many. In its order the FDA ruled that the California pharmaceutical company Orexigen must conduct more studies to rule out heart risks.
Last December, the FDA expert panel had opined that the drug was only modestly effective and was found to cause slight boosts in blood pressure and pulse and urged the company to conduct for a wider trial to assess potential heart attack risks.
In fact Contrave is made of two drugs -- bupropion and naltrexone -- that are already in widespread use Therefore the rejection of Contrave may seem crazy.
However, when one third of American population is obese and it is well known fact that obesity may cause heart risk and another anti-obesity drug is the need of the time then why did the FDA rejected Contrave itself?
But the important thing that the FDA mentioned that the drug is very little effective. One may argue that the obesity is a bigger problem than heart desease and in many cases it become the casue of the heart disease?
The problem is the drug may be effective in short term but in the long run it may risk life.
And in FDA’s opinion the drug is modestly effective so it is also not useful in prevent diabetes as it boosts blood pressure and pulse.
Speaking the truth FDAs refusal to the Contrave may seem wrong answer but that it's an answer to the wrong question.
The real issue is obesity that we should concentrate how to prevent obesity which is simply not a decease but a life style problem.